Similarly, gene mutations or problems in the production of the other hormones of the somatotropic axis and their receptors can cause a domino effect
doi: 10.3390/ijms22126574 57 Delgado-RocheL.MestaF
theoretical concerns about growth factor effects on occult malignancies Interaction potential with common medications not systematically evaluated Reproductive and endocrine effects requiring additional investigation Commercial Availability Challenges Manufacturing and regulatory issues affect availability: Product discontinued by original manufacturer in 2008 for commercial reasons unrelated to safety Currently available only through compounding pharmacies in the United States Quality control and potency standardization concerns with compounded formulations Lack of FDA oversight for compounded versions Regulatory & Competitive Sport Status FDA Position Sermorelins regulatory status reflects its complex history: FDA-approved 1997 for diagnosis and treatment of growth hormone deficiency in children Approved as diagnostic agent (Geref) for assessing growth hormone secretory capacity Manufacturing discontinued 2008 by Serono Laboratories for commercial viability reasons No longer available as FDA-approved pharmaceutical product Off-label prescribing permitted under medical supervision unlike recombinant growth hormone Available through compounding pharmacies without FDA approval oversight The FDA has not approved sermorelin for anti-aging, body composition enhancement, or athletic performance applications
Growth Hormone Release Moderate Research Research demonstrates significant, dose-dependent increases in growth hormone levels following Ipamorelin administration (PMID: 9849822), with peak GH concentrations occurring approximately 30-40 minutes post-injection (PMID: 10496658)
Additionally, these electrodes are linked to a pulse generator implanted in the thoracic cavity
It helps stimulate the bodys natural defense mechanisms, improving immune response and aiding in fighting infections
